GSA Capital Partners’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-54,385
Closed -$404K 2022
2026
Q1
$404K Buy
+54,385
New +$572K 0.03% 1053
2025
Q3
Sell
-47,956
Closed -$351K 1944
2025
Q2
$351K Buy
+47,956
New +$387K 0.02% 1161
2024
Q1
Sell
-11,479
Closed -$186K 1850
2023
Q4
$186K Buy
+11,479
New +$188K 0.02% 1337
2023
Q2
Sell
-20,949
Closed -$365K 1794
2023
Q1
$365K Buy
+20,949
New +$298K 0.04% 907
2021
Q2
Sell
-5,263
Closed -$254K 1509
2021
Q1
$254K Buy
+5,263
New +$274K 0.04% 752
2019
Q1
Sell
-55,245
Closed -$697K 1601
2018
Q4
$697K Buy
+55,245
New +$823K 0.08% 383
2017
Q4
Sell
-33,191
Closed -$369K 1728
2017
Q3
$369K Buy
+33,191
New +$323K 0.03% 1139
2015
Q1
Sell
-137,424
Closed -$573K 2171
2014
Q4
$573K Buy
137,424
+25,722
+23% +$118K 0.04% 841
2014
Q3
$582K Buy
111,702
+93,300
+507% +$479K 0.03% 832
2014
Q2
$61K Buy
+18,402
New +$61.2K ﹤0.01% 1744
2013
Q3
Sell
-37,450
Closed -$149K 1623
2013
Q2
$149K Buy
+37,450
New +$143K 0.02% 1163

Other funds holding NEO

GSA Capital Partners's NEO Position: Q2 2026 in Review

GSA Capital Partners sold out of NeoGenomics (NEO) in Q2 2026, closing a stake of 54,385 shares — an estimated $404K sold.

GSA Capital Partners first reported a position in NEO in Q2 2013 and held it in 11 quarters. The position peaked at $697K in Q4 2018. 267 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • GSA Capital Partners reported no remaining NeoGenomics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 54,385 NeoGenomics shares in Q2 2026, an estimated $404K.
  • GSA Capital Partners first reported a position in NeoGenomics in Q2 2013 and held it in 11 quarters.
  • GSA Capital Partners's NeoGenomics position peaked at $697K in Q4 2018.
  • 267 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.